Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study Post published:September 22, 2025 Post category:Analysis/News/Pα+
UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence Post published:September 19, 2025 Post category:Analysis/News/Pα+
Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos Post published:September 8, 2025 Post category:Analysis/News/Pα+
BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) Post published:September 4, 2025 Post category:Analysis/News
Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing Post published:September 3, 2025 Post category:Analysis/News/Pα+
AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B Post published:August 25, 2025 Post category:Analysis/News/Pα+
Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression Post published:August 25, 2025 Post category:Analysis/News/Pα+
Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression Post published:August 18, 2025 Post category:Analysis/News/Pα+
Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches Post published:August 5, 2025 Post category:Analysis/Interviews/News/Pα+
Germany Establishes EU’s First Psilocybin Compassionate Access Program Post published:July 31, 2025 Post category:Analysis/News